Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | KDM5A | P29375 | 3/20 | 0.51 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15880035 | 1.00 | TSHR (0.54) | TSHRTDP1ALOX15KDM4ELMNA | |
| SCHEMBL28575467 | 1.00 | TSHR (0.54) | TSHRTDP1ALOX15KDM4ELMNA | |
| SCHEMBL11512199 | 1.00 | TSHR (0.54) | TSHRTDP1ALOX15KDM4ELMNA | |
| SCHEMBL7568504 | 1.00 | TSHR (0.54) | TSHRTDP1ALOX15KDM4ELMNA | |
| SCHEMBL8588942 | 1.00 | TSHR (0.54) | TSHRTDP1ALOX15KDM4ELMNA | |
| SCHEMBL11316935 | 1.00 | TSHR (0.54) | TSHRTDP1ALOX15KDM4ELMNA | |
| SCHEMBL19040769 | 1.00 | TSHR (0.54) | TSHRTDP1ALOX15KDM4ELMNA | |
| SCHEMBL19821297 | 1.00 | TSHR (0.54) | TSHRTDP1ALOX15KDM4ELMNA | |
| SCHEMBL19821298 | 1.00 | TSHR (0.54) | TSHRTDP1ALOX15KDM4ELMNA | |
| SCHEMBL11317527 | 1.00 | TSHR (0.54) | TSHRTDP1ALOX15KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0074272-B1 | PROCESS FOR THE PREPARATION OF HYDROXYBENZALDEHYDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-08-13 | — | — | EP | claimed |
| CN-118647361-A | Nanoparticles for releasing nucleic acids | 克劳德伯纳德里昂第一大学 | 2024-09-13 | — | — | CN | disclosed |
| US-20220265857-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2022-08-25 | — | — | US | disclosed |
| EP-3386484-B1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11285222-B2 | Compositions and methods for delivery of agents | MODERNATX, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| CN-114026228-A | Optimization of engineered meganucleases for recognition sequences | 精密生物科学公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20200206362-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | Moderna TX, Inc. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200206362-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | Moderna TX, Inc. (US) | 2020-07-02 | — | — | US | disclosed |
| US-10556018-B2 | Compositions and methods for delivery of agents | ARES CAPITAL CORPORATION, AS AGENT | 2020-02-11 | — | — | US | disclosed |
| US-10556018-B2 | Compositions and methods for delivery of agents | ARES CAPITAL CORPORATION, AS AGENT | 2020-02-11 | — | — | US | disclosed |
| US-20150240295-A1 | REACTIVE, LIPOPHILIC NUCLEOSIDE BUILDING BLOCKS FOR THE SYNTHESIS OF HYDROPHOBIC NUCLEIC ACIDS | IONOVATION GMBH (DE) | 2015-08-27 | — | — | US | disclosed |
| US-20150240295-A1 | REACTIVE, LIPOPHILIC NUCLEOSIDE BUILDING BLOCKS FOR THE SYNTHESIS OF HYDROPHOBIC NUCLEIC ACIDS | IONOVATION GMBH (DE) | 2015-08-27 | — | — | US | disclosed |
| EP-2900681-A1 | REACTIVE, LIPOPHILIC NUCLEOSIDE BUILDING BLOCKS FOR THE SYNTHESIS OF HYDROPHOBIC NUCLEIC ACIDS | Ionovation GmbH (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-20020173456-A1 | Complex of macromolecules and peptide; supplying cells | BAYLOR COLLEGE OF MEDICINE | 2002-11-21 | — | — | US | disclosed |
| US-6344436-B1 | GENE DELIVERY TO CELLS | BAYLOR COLLEGE OF MEDICINE | 2002-02-05 | — | — | US | disclosed |
| US-5730956-A | DTPA di-alkyl monoamides for x-ray and MRI | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-03-24 | — | — | US | disclosed |
| EP-0810990-A1 | SUBSTITUTED DTPA MONOAMIDES OF CENTRAL CARBOXYLIC ACIDS AND METAL COMPLEXES THEREOF, PHARMACEUTICALS CONTAINING THESE COMPLEXES, DIAGNOSTIC AND THERAPEUTIC USES THEREOF AND METHODS FOR PREPARING THE COMPLEXES AND PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-12-10 | — | — | EP | disclosed |
| US-5679852-A | Process for the production of DTPA-monoamides of the central carboxylic acid and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-10-21 | — | — | US | disclosed |
| US-5676923-A | SOLUBLE, STABLE, ORGAN-SPECIFIC NUCLEAR MAGNETIC RESONANCE CONTRAST AGENT | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-10-14 | — | — | US | disclosed |
| WO-1996026182-A1 | SUBSTITUTED DTPA MONOAMIDES OF CENTRAL CARBOXYLIC ACIDS AND METAL COMPLEXES THEREOF, PHARMACEUTICALS CONTAINING THESE COMPLEXES, DIAGNOSTIC AND THERAPEUTIC USES THEREOF AND METHODS FOR PREPARING THE COMPLEXES AND PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556018-B2 | Compositions and methods for delivery of agents | HDLBP, APOB, TSG101 | TSHR 3374/4885TDP1 753/4885ALOX15 2829/4885 |
| US-20200206362-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | TSHR 3374/4885TDP1 753/4885ALOX15 2829/4885 |
| US-11285222-B2 | Compositions and methods for delivery of agents | HDLBP, APOB, TSG101 | TSHR 3374/4885TDP1 753/4885ALOX15 2829/4885 |
| US-20220265857-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | TSHR 3374/4885TDP1 753/4885ALOX15 2829/4885 |
| US-20150240295-A1 | REACTIVE, LIPOPHILIC NUCLEOSIDE BUILDING BLOCKS FOR THE SYNTHESIS OF HYDROPHOBIC NUCLEIC ACIDS | NCL, NOP2, POLRMT | TSHR 3545/4885TDP1 493/4885ALOX15 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.